BLOODPAC
@bloodpac.bsky.social
Accelerating the development and validation of #liquidbiopsy assays to improve the outcomes of patients with #cancer. Not-for-profit.
Whether our members are an early-stage company or an established organization, BLOODPAC’s quarterly meetings offer a unique space to collaborate, learn, and help shape the future of diagnostics. Our members say it best—this community makes a difference. Excited for our Q1 2026.
February 12, 2026 at 4:42 PM
Whether our members are an early-stage company or an established organization, BLOODPAC’s quarterly meetings offer a unique space to collaborate, learn, and help shape the future of diagnostics. Our members say it best—this community makes a difference. Excited for our Q1 2026.
We’re pleased to welcome Insightec as the newest member of BLOODPAC! Insightec is a global healthcare company advancing focused ultrasound medical technologies used in clinical practice worldwide.
Learn more at insightec.com.
Learn more at insightec.com.
February 10, 2026 at 3:59 PM
We’re pleased to welcome Insightec as the newest member of BLOODPAC! Insightec is a global healthcare company advancing focused ultrasound medical technologies used in clinical practice worldwide.
Learn more at insightec.com.
Learn more at insightec.com.
What makes BLOODPAC’s quarterly meetings special? A truly collaborative environment where industry, researchers, and innovators come together to focus and tackle shared challenges. Our members consistently highlight the value of learning, sharing, and building together. Q1 2026 meeting coming soon!
February 5, 2026 at 2:22 PM
What makes BLOODPAC’s quarterly meetings special? A truly collaborative environment where industry, researchers, and innovators come together to focus and tackle shared challenges. Our members consistently highlight the value of learning, sharing, and building together. Q1 2026 meeting coming soon!
BLOODPAC was active today at the 10th Liquid Biopsy for Precision Oncology Summit. Our ED Lauren Leiman moderated a panel on bridging innovation to access and led an interactive session on standardization. We highlighted how standardization accelerates validation and patient access.
February 4, 2026 at 10:47 PM
BLOODPAC was active today at the 10th Liquid Biopsy for Precision Oncology Summit. Our ED Lauren Leiman moderated a panel on bridging innovation to access and led an interactive session on standardization. We highlighted how standardization accelerates validation and patient access.
🎉 Let the countdown begin! 🎉 Just 1 month until BLOODPAC’s in-person first quarter meeting! Join us on March 4th and 5th in San Diego, California, hosted by Guardant Health. We can't wait to see everyone there!
February 4, 2026 at 5:16 PM
🎉 Let the countdown begin! 🎉 Just 1 month until BLOODPAC’s in-person first quarter meeting! Join us on March 4th and 5th in San Diego, California, hosted by Guardant Health. We can't wait to see everyone there!
Today our Executive Director joined a panel at the 10th Liquid Biopsy for Precision Oncology Summit, hosted by Personalis, discussing how ultrasensitive MRD testing may help accelerate clinical development and regulatory pathways. 🧬
February 3, 2026 at 11:40 PM
Today our Executive Director joined a panel at the 10th Liquid Biopsy for Precision Oncology Summit, hosted by Personalis, discussing how ultrasensitive MRD testing may help accelerate clinical development and regulatory pathways. 🧬
Tomorrow: BLOODPAC Executive Director Lauren Leiman will speak at Hanson Wade’s Liquid Biopsy for Precision Oncology Summit, presenting on standardization challenges and joining a panel on aligning standards, policy, and reimbursement.
lbx-summit.com
lbx-summit.com
February 3, 2026 at 7:59 PM
Tomorrow: BLOODPAC Executive Director Lauren Leiman will speak at Hanson Wade’s Liquid Biopsy for Precision Oncology Summit, presenting on standardization challenges and joining a panel on aligning standards, policy, and reimbursement.
lbx-summit.com
lbx-summit.com
BLOODPAC meetings aren’t just about networking—they’re about meaningful collaboration across diagnostics, data science, and regulation. Members value the chance to learn from peers and work toward shared solutions. Can't wait to see all our members at the Q1 2026.
January 30, 2026 at 3:29 PM
BLOODPAC meetings aren’t just about networking—they’re about meaningful collaboration across diagnostics, data science, and regulation. Members value the chance to learn from peers and work toward shared solutions. Can't wait to see all our members at the Q1 2026.
🎉 Welcome to BLOODPAC, @Twist Bioscience! 🧬
Twist Bioscience is a biotech company that develops & manufactures synthetic DNA using a silicon-based platform.
To learn more about Twist Bioscience, visit:
👉 www.twistbioscience.com
Twist Bioscience is a biotech company that develops & manufactures synthetic DNA using a silicon-based platform.
To learn more about Twist Bioscience, visit:
👉 www.twistbioscience.com
January 29, 2026 at 3:59 PM
🎉 Welcome to BLOODPAC, @Twist Bioscience! 🧬
Twist Bioscience is a biotech company that develops & manufactures synthetic DNA using a silicon-based platform.
To learn more about Twist Bioscience, visit:
👉 www.twistbioscience.com
Twist Bioscience is a biotech company that develops & manufactures synthetic DNA using a silicon-based platform.
To learn more about Twist Bioscience, visit:
👉 www.twistbioscience.com
BLOODPAC Executive Director Lauren Leiman will participate in Hanson Wade’s 10th Annual Liquid Biopsy for Precision Oncology Summit on Feb 4 in San Diego, presenting on standardization and joining a panel on policy and reimbursement. lbx-summit.com
10th Liquid Biopsy for Precision Oncology Summit
Celebrate 10 years of liquid biopsy innovation and progress at the Liquid Biopsy for Precision Oncology Summit happening next month
lbx-summit.com
January 28, 2026 at 4:43 PM
BLOODPAC Executive Director Lauren Leiman will participate in Hanson Wade’s 10th Annual Liquid Biopsy for Precision Oncology Summit on Feb 4 in San Diego, presenting on standardization and joining a panel on policy and reimbursement. lbx-summit.com
Mark your calendars! BLOODPAC’s Q1 2026 in-person meeting is coming this March in San Diego, hosted by Guardant Health. We’re looking forward to two days of collaboration, project updates, and driving innovation in liquid biopsy. See you soon!
January 21, 2026 at 3:09 PM
Mark your calendars! BLOODPAC’s Q1 2026 in-person meeting is coming this March in San Diego, hosted by Guardant Health. We’re looking forward to two days of collaboration, project updates, and driving innovation in liquid biopsy. See you soon!
One of the greatest strengths of BLOODPAC is bringing science, industry, and regulatory perspectives into the same room. Our quarterly meetings foster the kind of collaboration needed to move diagnostics forward responsibly.
We can't wait for our 2026 Q1 meeting! 🙌
We can't wait for our 2026 Q1 meeting! 🙌
January 20, 2026 at 5:28 PM
One of the greatest strengths of BLOODPAC is bringing science, industry, and regulatory perspectives into the same room. Our quarterly meetings foster the kind of collaboration needed to move diagnostics forward responsibly.
We can't wait for our 2026 Q1 meeting! 🙌
We can't wait for our 2026 Q1 meeting! 🙌
📣 New from BLOODPAC! Our MRD AV Working Group has published consensus protocols for analytical validation of tumor-informed ctDNA MRD assays—years in the making and announced today via press release.
🔗 Press: www.prnewswire.com/news-release...
#MRD #LiquidBiopsy
🔗 Press: www.prnewswire.com/news-release...
#MRD #LiquidBiopsy
BLOODPAC Publishes New Standards for Liquid Biopsy Tests That Monitor for Cancer Recurrence
/PRNewswire/ -- A new consensus document developed by The Blood Profiling Atlas in Cancer (BLOODPAC) Consortium was published in JCO Precision Oncology. The...
www.prnewswire.com
January 15, 2026 at 3:00 PM
📣 New from BLOODPAC! Our MRD AV Working Group has published consensus protocols for analytical validation of tumor-informed ctDNA MRD assays—years in the making and announced today via press release.
🔗 Press: www.prnewswire.com/news-release...
#MRD #LiquidBiopsy
🔗 Press: www.prnewswire.com/news-release...
#MRD #LiquidBiopsy
🚨 New update! The BLOODPAC Dictionary now includes terms from Lexicon for Clonal Hematopoiesis in Liquid Biopsy, our first CH/CHIP Working Group paper. Explore the full paper & dictionary on our website! www.bloodpac.org
January 14, 2026 at 9:40 PM
🚨 New update! The BLOODPAC Dictionary now includes terms from Lexicon for Clonal Hematopoiesis in Liquid Biopsy, our first CH/CHIP Working Group paper. Explore the full paper & dictionary on our website! www.bloodpac.org
Looking back at our Q3 2025 meeting, members like Andrew Anfora shared why BLOODPAC’s quarterly meetings matter—bringing years of collaboration together. We’re excited to carry that momentum into our Q1 2026 meeting.
January 14, 2026 at 6:47 PM
Looking back at our Q3 2025 meeting, members like Andrew Anfora shared why BLOODPAC’s quarterly meetings matter—bringing years of collaboration together. We’re excited to carry that momentum into our Q1 2026 meeting.
Exciting news! BLOODPAC’s in-person Q1 2026 meeting is happening this March - hosted by our valued member, @guardanthealth.bsky.social, in San Diego, CA.
Join us for two impactful days of collaboration, knowledge sharing, and progress updates on our key initiatives.
Join us for two impactful days of collaboration, knowledge sharing, and progress updates on our key initiatives.
January 8, 2026 at 7:14 PM
Exciting news! BLOODPAC’s in-person Q1 2026 meeting is happening this March - hosted by our valued member, @guardanthealth.bsky.social, in San Diego, CA.
Join us for two impactful days of collaboration, knowledge sharing, and progress updates on our key initiatives.
Join us for two impactful days of collaboration, knowledge sharing, and progress updates on our key initiatives.
🙌 We’re excited to announce Lexicon for #ClonalHematopoiesis in #LiquidBiopsy, the first paper from our CH/CHIP Working Group. This lexicon standardizes terminology to improve communication and consistency in liquid biopsy research and clinical use.
🔗 Read more: bit.ly/BP-CH-lexicon
🔗 Read more: bit.ly/BP-CH-lexicon
January 7, 2026 at 4:17 PM
🙌 We’re excited to announce Lexicon for #ClonalHematopoiesis in #LiquidBiopsy, the first paper from our CH/CHIP Working Group. This lexicon standardizes terminology to improve communication and consistency in liquid biopsy research and clinical use.
🔗 Read more: bit.ly/BP-CH-lexicon
🔗 Read more: bit.ly/BP-CH-lexicon
Looking back on everything we achieved last year. Huge thanks to our amazing team and members. Your hard work drives every milestone. 💙
Take a peek at our 2025 highlights below, and here’s to an even better 2026! ✨
Take a peek at our 2025 highlights below, and here’s to an even better 2026! ✨
January 6, 2026 at 5:25 PM
Looking back on everything we achieved last year. Huge thanks to our amazing team and members. Your hard work drives every milestone. 💙
Take a peek at our 2025 highlights below, and here’s to an even better 2026! ✨
Take a peek at our 2025 highlights below, and here’s to an even better 2026! ✨
Welcome Biofidelity to the BLOODPAC Consortium! Their technologies aim to advance precision oncology and improve access to high-quality genomic insights. We’re excited to work together to accelerate progress across the liquid biopsy ecosystem.
#BLOODPAC #Biofidelity
#BLOODPAC #Biofidelity
December 3, 2025 at 3:04 PM
Welcome Biofidelity to the BLOODPAC Consortium! Their technologies aim to advance precision oncology and improve access to high-quality genomic insights. We’re excited to work together to accelerate progress across the liquid biopsy ecosystem.
#BLOODPAC #Biofidelity
#BLOODPAC #Biofidelity
How should we measure performance for blood-based early detection? Our Summer Seminar tackled modern metrics, diagnostic yield, and what clinicians/patients actually need.
👉Read the recap: www.bloodpac.org/bloodpac-blo...
👉Watch the recording: www.bloodpac.org/performance-...
👉Read the recap: www.bloodpac.org/bloodpac-blo...
👉Watch the recording: www.bloodpac.org/performance-...
Performance with Metrics in Early Detection — BLOODPAC
In this blog we recap our Early Detection & Screening (ED&S) Working Group’s summer seminar “Performance with Purpose: Metrics that Inform Clinical and Public Health Decisions,” which took pla...
www.bloodpac.org
November 18, 2025 at 3:34 PM
How should we measure performance for blood-based early detection? Our Summer Seminar tackled modern metrics, diagnostic yield, and what clinicians/patients actually need.
👉Read the recap: www.bloodpac.org/bloodpac-blo...
👉Watch the recording: www.bloodpac.org/performance-...
👉Read the recap: www.bloodpac.org/bloodpac-blo...
👉Watch the recording: www.bloodpac.org/performance-...
We were proud to join #AMP2025!
Our Executive Director, Lauren Leiman, moderated “Demystifying MRD with BLOODPAC,” joined by leaders from Illumina, Harvard, BMS & BLOODPAC to discuss best practices and innovation in cancer monitoring. #MRD #LiquidBiopsy #Oncology
Our Executive Director, Lauren Leiman, moderated “Demystifying MRD with BLOODPAC,” joined by leaders from Illumina, Harvard, BMS & BLOODPAC to discuss best practices and innovation in cancer monitoring. #MRD #LiquidBiopsy #Oncology
November 13, 2025 at 8:21 PM
We were proud to join #AMP2025!
Our Executive Director, Lauren Leiman, moderated “Demystifying MRD with BLOODPAC,” joined by leaders from Illumina, Harvard, BMS & BLOODPAC to discuss best practices and innovation in cancer monitoring. #MRD #LiquidBiopsy #Oncology
Our Executive Director, Lauren Leiman, moderated “Demystifying MRD with BLOODPAC,” joined by leaders from Illumina, Harvard, BMS & BLOODPAC to discuss best practices and innovation in cancer monitoring. #MRD #LiquidBiopsy #Oncology
We’re excited to welcome nRichDX as BLOODPAC’s newest member! Their patented Revolution Sample Prep System™ aims to advance liquid biopsy by maximizing recovery of rare analytes to improve diagnostic accuracy.
🔗 nrichdx.com
🔗 nrichdx.com
November 13, 2025 at 3:45 PM
We’re excited to welcome nRichDX as BLOODPAC’s newest member! Their patented Revolution Sample Prep System™ aims to advance liquid biopsy by maximizing recovery of rare analytes to improve diagnostic accuracy.
🔗 nrichdx.com
🔗 nrichdx.com
Excited to share that BLOODPAC Executive Director, Lauren Leiman, will moderate “Demystifying MRD with BLOODPAC” at #AMP2025 on Nov 12, 4–4:50 PM in Boston!
Join experts from Illumina, HMS, BMS & BLOODPAC to explore the future of MRD testing.
#LiquidBiopsy #Oncology
Join experts from Illumina, HMS, BMS & BLOODPAC to explore the future of MRD testing.
#LiquidBiopsy #Oncology
November 12, 2025 at 4:05 PM
Excited to share that BLOODPAC Executive Director, Lauren Leiman, will moderate “Demystifying MRD with BLOODPAC” at #AMP2025 on Nov 12, 4–4:50 PM in Boston!
Join experts from Illumina, HMS, BMS & BLOODPAC to explore the future of MRD testing.
#LiquidBiopsy #Oncology
Join experts from Illumina, HMS, BMS & BLOODPAC to explore the future of MRD testing.
#LiquidBiopsy #Oncology
Huge thanks to all who joined our 4th Annual BLOODPAC New Frontiers Seminar: “New Frontiers in Therapy Selection: Beyond DNA Mutations.” Inspiring talks & discussions on the future of precision oncology! Highlights coming soon! #LiquidBiopsy #TherapySelection #PrecisionOncology #BLOODPAC
November 6, 2025 at 5:00 PM
Huge thanks to all who joined our 4th Annual BLOODPAC New Frontiers Seminar: “New Frontiers in Therapy Selection: Beyond DNA Mutations.” Inspiring talks & discussions on the future of precision oncology! Highlights coming soon! #LiquidBiopsy #TherapySelection #PrecisionOncology #BLOODPAC
Thank you to ISLB and Dr. Christian Rolfo for an inspiring 7th Annual Congress of Liquid Biopsy! Our Executive Director, Lauren Leiman, joined experts from BLOODPAC member organizations—Thermo Fisher, Guardant, Foundation Medicine/Roche, and Natera—to discuss translation of LBx into the clinic.
November 4, 2025 at 4:26 PM
Thank you to ISLB and Dr. Christian Rolfo for an inspiring 7th Annual Congress of Liquid Biopsy! Our Executive Director, Lauren Leiman, joined experts from BLOODPAC member organizations—Thermo Fisher, Guardant, Foundation Medicine/Roche, and Natera—to discuss translation of LBx into the clinic.